Celyad (NASDAQ:CYAD) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

Separately, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $74.00 price objective on shares of Celyad in a research note on Monday, October 9th.

Shares of Celyad (CYAD) traded down $1.61 during trading on Friday, hitting $40.39. 529 shares of the company traded hands, compared to its average volume of 2,780. Celyad has a 12 month low of $16.73 and a 12 month high of $64.75.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/03/celyad-cyad-downgraded-by-valuengine-to-sell.html.

Celyad Company Profile

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with MarketBeat.com's FREE daily email newsletter.